Arkansas is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132
Recruiting
This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2 Study 12-AVR-131 to be included.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
05/22/2024
Locations: Health Initiatives Research, Fayetteville, Arkansas
Conditions: Agitation in Patients With Dementia of the Alzheimer's Type
Register for Updates
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496
Recruiting
The goal of this study is to assess and compare the effectiveness of fluticasone furoate/umeclidinium bromide/vilanterol trifenatate (FF/UMEC/VI) with inhaled corticosteroids/long-acting beta-2 agonists (ICS/LABA) in adult participants with uncontrolled asthma
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/21/2024
Locations: GSK Investigational Site, Little Rock, Arkansas
Conditions: Asthma
Register for Updates
A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)
NCT06273774
Recruiting
The goal of this study is to evaluate the safety and tolerability of MK-8189 in participants with stable bipolar I disorder. There will be no hypothesis testing in this study.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/21/2024
Locations: Woodland International Research Group-Clinical Research ( Site 0009), Little Rock, Arkansas
Conditions: Bipolar I Disorder
Register for Updates
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
NCT06143046
Recruiting
The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
05/21/2024
Locations: Applied Research Center of Arkansas - ClinEdge - PPDS, Little Rock, Arkansas
Conditions: Respiratory Syncytial Virus
Register for Updates
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782
Recruiting
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab (MK-3475A) administered subcutaneously (SC) over pembrolizumab (MK-3475) administered intravenously (IV) in participants with multiple tumor types. There will be no hypothesis testing in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Highlands Oncology Group-Research Department ( Site 0133), Springdale, Arkansas
Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Register for Updates
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
NCT05831189
Recruiting
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy. More specifically, the purpose of this trial is to explore the safety and clinical effectiveness of RBX2660 when delivered by colonoscopy to adults with rCDI. The experience of physicians will be documented through a physician-experience questionnaire to explore the usability of RBX2660 in clinical practice for colonoscopic administration. Furthermore, to explor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Ferring Investigational Site, North Little Rock, Arkansas
Conditions: Clostridium Difficile Infection Recurrence
Register for Updates
Long-term Extension Study of Ligelizumab in Food Allergy
NCT05678959
Recruiting
This is an extension study to evaluate the long-term safety and efficacy of ligelizumab in particiants who have completed a ligelizumab Phase III study in food allergy.
Gender:
All
Ages:
Between 6 years and 57 years
Trial Updated:
05/21/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Food Allergy
Register for Updates
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001
Recruiting
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Little Rock Allergy and Asthma Clnc, Little Rock, Arkansas
Conditions: Chronic Spontaneous Urticaria
Register for Updates
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
NCT05432388
Recruiting
A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy will be measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
05/21/2024
Locations: Arkansas Children's Hospital Main Centre, Little Rock, Arkansas
Conditions: Allergy, Peanut
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
Non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Mercy Clinic Oncology - Fort Smith, Fort Smith, Arkansas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177
Recruiting
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Mercy Clinic Oncology - Fort Smith, Fort Smith, Arkansas
Conditions: Colorectal Cancer
Register for Updates
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
NCT05997017
Recruiting
A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Michael Birrer, MD, PhD, Little Rock, Arkansas
Conditions: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Register for Updates